Why prevent, diagnose and treat congenital toxoplasmosis?

Memorias do Instituto Oswaldo Cruz

Volumn 104, Issue 2, 2009, Pages 320-344

  McLeod, Rima ^a   Kieffer, Francois ^b   Sautter, Mari ^a   Hosten, Tiffany ^a   Pelloux, Herve ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b Institut de Puericulture   (France)

^c Institut Jean Roget   (France)

Author keywords

Congenital toxoplasmosis; Prevention; Treatment

Indexed keywords

ANIMALIA; MAMMALIA; PRIMATES; TOXOPLASMA GONDII;

EID: 65549156690     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762009000200029     Document Type: Article

References (208)

1. Aagaard K, Melchior J 1959. The simultaneous occurrence of congenital toxoplasmosis and congenital myxoedema. Acta Paedeatrica 48: 164-168.
2. Ajzenberg D, Cogne N, Paris L, Bessieres MH, Thulliez P, Filisetti D, Pelloux H, Marty P, Darde ML 2002. Genotype of 86 Toxoplasma gondii isolates associated with human congenital toxoplasmosis and correlation with clinical findings. J Infect Dis 186: 684-689.
3. Alford C, Foft J, Blankenship W, Cassady G, Benton J 1969. Subclinical central nervous system disease of neonates: a prospective study of infants born with increased levels of IgM. J Pediatr 75: 1167-1178.
4. Alford CA, Schaefer J, Blankenship WJ, Straumfjord JV, Cassady G 1967. A correlative immunologic, microbiologic and clinical approach to the diagnosis of acute and chronic infections in newborn infants. N Engl J Med 277: 437-449.
5. Alford CA Jr, Reynolds DW, Stagno S 1975. Current concepts of chronic perinatal infections. In L Gluck (ed.), Modern Perinatal Medicine, Year Book Medical Publishers, Chicago, p. 285-306.
6. Alford CJ, Stagno S, Reynolds DW 1974. Congenital toxoplasmosis: clinical, laboratory and therapeutic considerations, with special reference to subclinical disease. Bull N Y Acad Med 50: 160-181.
7. Andrade GM, Resende LM, Goulart EM, Siqueira AL, Vitor RW, Januario JN 2008. Hearing loss in congenital toxoplasmosis detected by newborn screening. Rev Bras Otorrinolaringol 74: 21-28.
8. Araujo FG, Prokocimer P, Lin T, Remington JS 1992. Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. Antimicrob Agents Chemother 36: 2454-2457.
9. Aspöck H 1996. Österreichs Beitrag zur Toxoplasmose-Forschung und 20 Jahre Toxoplasmose-Überwachung der Schwangeren in Österreich. Tropenmend Parasitol 18: 1-18.
10. Aspöck H, Flamm H, Picher O 1986. Toxoplasmosis surveillance during pregnancy-10 years of experience in Austria. Mitt Osterr Ges Tropenmed Parasitol 8: 105-113.
11. Aspöck H, Pollak A 1992. Prevention of prenatal toxoplasmosis by serological screening of pregnant women in Austria. Scand J Infect Dis 84 (Suppl.): 32-37.
12. Bain A, Bowie J, Flint W, Beverley J, Beattie C 1956. Congenital toxoplasmosis simulating haemolytic disease of the newborn. Br J Obstet Gyn 63: 826-832.
13. Benevento JD, Jager RD, Noble AG, Latkany P, Mieler WF, Sautter M, Meyers S, Mets M, Grassi MA, Rabiah P, Boyer K, Swisher C, McLeod R, Toxoplasmosis Study Group 2008. Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol 126: 1152-1156.
14. Berger F, Goulet V, Le Strat Y, Desenclos JC 2008. Toxoplasmose chez les femmes enceintes en France: evolution de la seroprevalence et de l'incidence et facteurs associes, 1995-2003. Available from http:www.invs.sante.fr/beh/2008/14_15/index.htm.
15. Berrebi A, Bardou M, Bessieres MH, Nowakowska D, Castagno R, Rolland M, Wallon M, Franck J, Bongain A, Monnier-Barbarino P, Assouline C, Cassaing S 2007. Outcome for children infected with congenital toxoplasmosis in the first trimester and with normal ultrasound findings: a study of 36 cases. Eur J Obstet Gynecol Reprod Biol 135: 53-57.
16. Berrebi A, Kobuch WE, Bessieres MH, Bloom MC, Rolland M, Sarramon MF, Roques C, Fournié A 1994. Termination of pregnancy for maternal toxoplasmosis. Lancet 344: 36-39.
17. Beverley JKA, Freeman AP, Henry L, Whelan JPF 1973. Prevention of pathological changes in experimental congenital toxoplasma infections. Lyon Medical 230: 491-498.
18. Binquet C, Wallon M, Quantin C, Kodjikian L, Garweg J, Fleury J, Peyron F, Abrahamowicz M 2003. Prognostic factors for the long-term development of ocular lesions in 327 children with congenital toxoplasmosis. Epidemiol Infect 131: 1157-1168.
19. Blaakaer J 1986. Ultrasonic diagnosis of fetal ascites and toxoplasmosis. Acta Obstet Gynecol Scand 65: 653-654.
20. Boothroyd JC, Grigg ME 2002. Population biology of Toxoplasma gondii and its relevance to human infection: do different strains cause different disease? Curr Opin Microbiol 5: 438-442.
21. Boulton M, Haines L, Smyth D, Fielder A 2006. Health-related quality of life of children with vision impairment or blindness. Dev Med Child Neurol 48: 656-661.
22. Boyer K, Holfels E, Roizen N, Swisher C, Mack D, Remington J, Withers S, Meier P, Karrison T, Mcleod R 2005. Risk factors for Toxplasma gondii infection in mothers of infants with congenitial toxoplasmosis: implications for prenatal management and screening. AJOG 192: 564-571.
23. Boyer K, Marcinak J, McLeod R 2008. Toxoplasma gondii (toxoplasmosis). In S Long, LK Pickering, CG Prober (eds.), Principles and practice of pediatric infectious diseases, 3rd ed., Churchill Livingstone, New York, section 274.
24. Boyer K, Roizen N, Rabiah P, Swisher C, Stein L, Patel D, Heydemann P, Hopkins J, Pfiffner L, Mets M, Mack D, Meier P, Holfels E, Withers S, McLeod R 2000. The child with congenital toxoplasmosis. In JS Remington (ed.), Current clinical topics in infectious diseases, New York, p. 189-207.
25. Brézin AP, Thulliez P, Couvreur J, Nobre R, Mcleod R, Mets MB 2003. Ophthalmic outcomes after prenatal and postnatal treatment of congenital toxoplasmosis. Am J Ophthalmol 35: 779-784.
26. Bruhl HH, Bahn RC, Hayles AB 1958. Sexual precocity associated with congenital toxoplasmosis. Proc Staff Meet Mayo Clin 33: 682-686.
27. Brus R, Chrusciel TL, Steffen J, Szaflarski J 1971. Antitoxoplasmic activity of sulfonamides with various radicals in experimental toxoplasmosis in mice. Z Tropenmed Parasitol 22: 98-103.
28. Caiaffa WT, Chiari CA, Figueiredo AR, Orefice F, Antunes CM 1993. Toxoplasmosis and mental retardation-report of a case-control study. Mem Inst Oswaldo Cruz 88: 253-261.
29. Camargo-Neto E, Anele E, Rubim R, Brites A, Schute J, Becker D, Tuuminen T 2000. High prevalence of congenital toxoplasmosis in Brazil estimated in a 3-year prospective neonatal screening study. Int J Epidemiol 29: 941-947.
30. Coffey JJ 1985. Congenital toxoplasmosis 38 years ago (letter to the editor). Pediatr Infect Dis 4: 214.
31. Collins AT, Cromwell LD 1980. Computed tomography in the evaluation of congenital cerebral toxoplasmosis. J Comput Assist Tomogr 4: 326-329.
32. Coppola A, Spera C, Varcaccio G, Gargiulo A, Nasti A 1987. Partial anterior hypopituitarism caused by toxoplasmosis congenita. Description of a clinical case. Minerva Med 78: 403-410.
33. Couvreur J 1971. Prospective study of acquired toxoplasmosis in pregnant women with a special reference to the outcome of the fetus. In D Hentsch (ed.), Toxoplasmosis, Hans Huber Publishers, Bern, p. 119-136.
34. Couvreur J 1991. In utero treatment of congenital toxoplasmosis with a pyrimethamine-sulfadiazine combination. Presse Med 20: 1137.
35. Couvreur J, Desmonts G 1962. Congenial and maternal toxoplasmosis. A review of 300 congenital cases. Dev Med Child Neurol 4: 519-530.
36. Couvreur J, Desmonts G 1964. Les poussées évolutives tardives de la toxoplasmose congénitale. Cah Coll Med Hop Paris 5: 752-758.
37. Couvreur J, Desmonts G, Aron-Rosa D 1984a. Le prognostic oculare de la toxoplasmose congenitale: role du traitement. Ann Pediatr 31: 855-858.
38. Couvreur J, Desmonts G, Tournier G 1985. Etude d'une serie homogene de 210 cas de toxoplasmose congénitale chez des nourrissons ages de 0 à 11 mois et depistes de facon prospective. Sem Hop Paris 61: 3015-3019.
39. Couvreur J, Desmonts G, Tournier G, Szusterkac M 1984b. A homogeneous series of 210 cases of congenital toxoplasmosis in 0 to 11-month-old infants detected prospectively. Ann Pediatr (Paris) 31: 815-819.
40. Couvreur J, Thulliez P, Daffos F, Aufrant C, Bompard Y, Gesquière A, Desmonts G 1993. In utero treatment of toxoplasmic fetopathy with the combination pyrimethamine-sulfadiazine. Fetal Diagn Ther 8: 45-50.
41. Cunningham GC, Hawes WE, Madore C 1976. Intrauterine growth and neonatal risk in California. State of California Department of Health, Sacramento, cited in Pediatrics 66: 1980, p. 774.
42. Daffos F, Forestier F, Capella-Pavlovsky M, Thulliez P, Aufrant C, Valenti D, Cox WL 1988. Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. N Engl J Med 318: 271-275.
43. Dannemann B, McCutchan JA, Israelski D, Antoniskis D, Leport C, Luft B, Nussbaum J, Clumeck N, Morlat P, Chiu J, Vilde JL, Orellana M, Feigal D, Bartok A, Heseltine P, Leedom J, Remington J 1992. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med 116: 33-43.
44. Dardé ML, Villena I, Pinon JM, Beguinot I 1998. Severe toxoplasmosis caused by a Toxoplasma gondii strain with a new isoenzyme type acquired in French Guyana. J Clin Microbiol 1: 324.
45. Demar M, Ajzenberg D, Maubon D, Djossou F, Panchoe D, Punwasi W, Valery N, Peneau C, Daigre JL, Aznar C, Cottrelle B, Terzan L, Dardé ML, Carme B 2007. Fatal outbreak of human toxoplasmosis along the Maroni River: epidemiological, clinical and parasitological aspects. Clin Infect Dis 45: e88-95.
46. Derouin F 2001. Anti-toxoplasmosis drugs. Curr Opin Investig Drugs 2: 1368-1374.
47. Desmonts G 1982. Acquired toxoplasmosis in pregnant women. Evaluation of the frequency of transmission of Toxoplasma and of congenital toxoplasmosis. Lyon Med 248: 115-123.
48. Desmonts G 1985. Prevention de la toxoplasmosis: remarques sur l'experience poursuivie en France. In M Marois (ed.), Prevention of physical and mental congenital defects, Part B: Epidemiology, early detection and therapy, and environmental factors, Alan R Liss, New York, p. 313-316.
49. Desmonts G 1987. Central nervous system toxoplasmosis (letter to the editor). Pediatr Infect Dis J 6: 872-873.
50. Desmonts G, Couvreur J 1974a. Congenital toxoplasmosis. A prospective study of 378 pregnancies. N Engl J Med 290: 1110-1116.
51. Desmonts G, Couvreur J 1974b. Toxoplasmosis in pregnancy and its transmission to the fetus. Bull NY Acad Med 50: 146-159.
52. Desmonts G, Couvreur J 1984. Congenital toxoplasmosis. Prospective study of the outcome of pregnancy in 542 women with toxoplasmosis acquired during pregnancy. Ann Pediatr (Paris) 31: 805-809.
53. Desmonts G, Daffos F, Forestier F, Capella-Pavlovsky M, Thulliez P, Chartier M 1985. Prenatal diagnosis of congenital toxoplasmosis. Lancet 1: 500-504.
54. Diebler C, Dusser A, Dulac O 1985. Congenital toxoplasmosis. Clinical and neuroradiological evaluation of the cerebral lesions. Neuroradiology 27: 125-130.
55. Dubey JP, Graham DH, Blackston CR, Lehmann T, Gennari SM, Ragozo AM, Nishi SM, Shen SK, Kwok OC, Hill DE, Thulliez P 2002. Biological and genetic characterization of Toxoplasma gondii isolates from chickens (Gallus domesticus) from São Paulo, Brazil: unexpected findings. Int J Parasitol 32: 99.
56. Dubey JP, Graham DH, da Silva DS, Lehmann T, Bahia-Oliveira LM 2003. Toxoplasma gondii isolates of free ranging chickens from Rio de Janeiro, Brazil: mouse mortality, genotype, and oocyst shedding by cats. J Parasitol 89: 851.
57. Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R 1999. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counseling. Lancet 353: 1829-1833.
58. Dunn D, Weisberg LA 1984. Serial changes in a patient with congenital CNS toxoplasmosis as observed with CT. Comput Radiol 8: 133-139.
59. Dyke CG, Wolfe A, Cowen D, Paige B, Caffey J 1942. Toxoplasmis encephalomyelitis VIII. Significance of roentgenographic findings in the diagnosis of infantile or congenital toxoplasmosis. Am J Roentgenol 47: 830-844.
60. Eichenwald HF 1960. A study of congenital toxoplasmosis, with particular emphasis on clinical manifestations, sequelae and therapy. In JC Siim (ed.), Human toxoplasmosis, Munksgaard, Copenhagen, p. 41-49.
61. Eyles DE, Coleman N 1953a. Synergistic effect of sulfadiazine and daraprim against experimental toxoplasmosis in the mouse. Antibiot Chemother 3: 483-490.
62. Eyles DE, Coleman N 1953b. The relative activity of the common sulfonamides against toxoplasmosis in the mouse. Am J Trop Med Hyg 2: 54-63.
63. Eyles DE, Coleman N 1955a. An evaluation of the curative effects of pyrimethamine and sulfadiazine, alone and in combination, on experimental mouse toxoplasmosis. Antibiot Chemother 5: 529-539.
64. Eyles DE, Coleman N 1955b. The effect of sulfadimetine, sulfisoxazole, and sulfapyrazine against mouse toxoplasmosis. Antibiot Chemother 5: 525-528.
65. Feldman HA 1963. Congenital toxoplasmosis. Letter to the editor. N Eng J Med 26: 1212.
66. Feldman HA 1973. Effects of trimethoprim and sulfisoxazole alone and in combination on murine toxoplasmosis. J Infect Dis 128: S774-S776.
67. Flamm H, Aspöck H 1981. Toxoplasmosis surveillance during pregnancy in Austria-results and problems. Padiatr Grenzgeb 20: 27-34.
68. Foulon W, Naessens A, Derde M 1994. Evaluation of the possibilities for preventing congenital toxoplasmosis. Am J Perinatol 11: 57-62.
69. Foulon W, Villena I, Stray-Pedersen B, Decoster A, Lappalainen M, Pinon JM, Jenum PA, Hedman K, Naessens A 1999. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol 180: 410-415.
70. Freeman K, Salt A, Prusa A, Malm G, Ferret N, Buffolano W, Schmidt D, Tan HK, Gilbert RE, European Multicentre Study on Congenital Toxoplasmosis 2005. Association between congenital toxoplasmosis and parent-reported developmental outcomes, concerns, and impairments, in 3 year old children. BMC Pediatr 5: 23.
71. Freeman K, Tan HK, Prusa A, Petersen E, Buffolano W, Malm G, Cortina-Borja M, Gilbert R, European Multicentre Study on Congenital Toxoplasmosis 2008. Predictors of retinochoroiditis in children with congenital toxoplasmosis: European, prospective cohort study. Pediatrics 121: e1215-22.
72. Frenkel JK, Friedlander S 1951. Toxoplasmosis: pathology of neonatal disease, Pathogenesis, diagnosis and treatment, USA Government Printing Office, Washington, Publication n 141. US Public Health Service, p. 107.
73. Frenkel JK, Hitchings GH 1957. Relative reversal by vitamins (p- Aminobenzoic, folic and folinic acids) of the effects of sulfadiazine and pyrimethamine on toxoplasma, mouse and man. Antibiot Chemother 7: 630-638.
74. Freudenberg E 1947. Akute infantile toxoplasmosis-Enzephalitis. Schweiz Med Wochenschr 77: 680-682.
75. Friedman S, Ford-Jones LE, Toi A, Ryan G, Blaser S, Chitayat D 1999. Congenital toxoplasmosis: prenatal diagnosis, treatment and postnatal outcome. Prenat Diagn 19: 330-333.
76. Garin JP, Brossier N, Sung RTM, Moyne T 1985. Effect of pyrimethamine sulfadoxine (Fansidar) on an avirulent cystogenic strain of Toxoplasma gondii (Prugniaud strain) in white mice. Bull Soc Pathol Exot Filiales 78: 821-824.
77. Garin JP, Paillard B 1984. Experimental toxoplasmosis in mice. Comparative activity of clindamycin, midecamycin, josamycin, spiramycin, pyrimethamine-sulfadoxine and trimethoprim-sulfamethoxazole. Ann Pediatr (Paris) 31: 841-845.
78. Garin JP, Pellerat J, Maillard, Woehrle R, Hezez 1968. Theoretical bases of the prevention by spiramycin of congenital toxoplasmosis in pregnant women. Presse Med 76: 2266.
79. Garza-Leon M, Muccioli C, Arellanes-Garcia L 2008. Toxoplasmosis in pediatric patients. Int Ophthalmol Clin 48: 75-85.
80. Gilbert R, Dezateux C 2006. Newborn screening for congenital toxoplasmosis: feasible, but benefits are not established. Arch Dis Child 91: 629-631.
81. Gilbert R, Gras L, European Multicentre Study on Congenital Toxoplasmosis 2003. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG 110: 112-120.
82. Gilbert RE, Freeman K, Lago EG, Bahia-Oliveira LM, Tan HK, Wallon M, Buffolano W, Stanford MR, Petersen E, The European Multicentre Study on Congenital Toxoplasmosis (EMSCOT) 2008. Ocular sequelae of congenital toxoplasmosis in Brazil compared with Europe. PLoS Negl Trop Dis 2: e277.
83. Gilbert RE, Gras L, Wallon M, Pekyron F, Ades AE, Dunn DT 2001. Effect of prenatal treatment on mother to child transmission of Toxoplasma gondii: retrospective study of 554 mother-child pairs in Lyon, France. Int J Epidemiol 30: 1303-1308.
84. Glasner PD, Silveira C, Kruszon-Moran D, Martins MC, Burnier Júnior M, Silveira S, Camargo ME, Nussenblatt RB, Kaslow RA, Belfort Júnior R 1992. An unusually high prevalence of ocular toxoplasmosis in Southern Brazil. Am J Ophthalmol 114: 136-144.
85. Gomez-Marin JE, Montoya-de-Londondo MT, Castano-Osorio JC 1997. A maternal screening program for congenital toxoplasmosis in Quindio, Colombia and application of mathematical models to estimate incidences using age-stratified data. Am J Trop Med Hyg 57: 180-186.
86. Gras L, Gilbert RE, Ades AE, Dunn DT 2001. Effect of prenatal treatment on the risk of intracranial and ocular lesions in children with congenital toxoplasmosis. Obstet Gynecol 30: 1309-1313.
87. Gras L, Wallon M, Pollak A, Cortina-Borja M, Evengard B, Hayde M, Petersen E, Gilbert R, European Multicenter Study on Congenital Toxoplasmosis 2005. Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. Acta Paediatr 94: 1721-1731.
88. Grigg ME, Ganatra J, Boothroyd JC, Margolis TP 2001. Unusual abundance of atypical strains associated with human ocular toxoplasmosis. J Infect Dis 184: 633-639.
89. Griscom NT, Colodny AH, Rosenberg HK, Fliegel CP, Hardy BE 1977. Diagnostic aspects of neonatal ascites: report of 27 cases. AJR Am J Roentgenol 128: 961-969.
90. Grossman PL, Remington JS 1979. The effect of trimethoprim and sulfamethoxazole on Toxoplasma gondii in vitro and in vivo. Am J Trop Med Hyg 28: 445-455.
91. Guerina NG, Hsu HW, Meissner HC, Maguire JH, Lynfield R, Stechenberg B, Abroms I, Pasternack MS, Hoff R, Eaton RB, Grady GF, New England Regional Toxoplasma working Group 1994.Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. N Engl J Med 330: 1858-1863.
92. Hall EG, Hay JD, Moss PD, Ryan MM 1953. Congenital toxoplasmosis in newborn. Arch Dis Child 28: 117-124.
93. Harper JS 3rd, London WT, Sever JL 1985. Five drug regimens for treatment of acute toxoplasmosis in squirrel monkeys. Am J Trop Med Hyg 34: 50-57.
94. Hedenstrom G, Huldt G, Lagercrantz R 1961. Toxoplasmosis in children. A study of 83 Swedish cases. Acta Paediatr 50: 304-312.
95. Hervei S, Simon K 1979. Congenital toxoplasmosis mimicking a cerebral tumor. Special aspects in serodiagnostics of connatal toxoplasmosis (author's transl). Monatsschr Kinderheilkd 127: 43-47.
96. Hogan MJ, Kimura SJ, Lewis A, Zweigart PA 1957. Early and delayed ocular manifestations of congenital toxoplasmosis. Trans Am Ophthalmol Soc 55: 275-296.
97. Hohlfeld P, Daffos F, Costa JM, Thulliez P, Forestier F, Vidaud M 1994a. Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid. N Engl J Med 331: 695-699.
98. Hohlfeld P, Daffos F, Thulliez P, Aufrant C, Couvreur J, MacAleese J, Descombey D, Forestier F 1989. Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr 115: 765-769.
99. Hohlfeld P, Forestier F, Kaplan C, Tissot J-D, Daffos F 1994b. Fetal thrombocytopenia: a retrospective survey of 5,194 fetal blood samplings. Blood 84: 1851-1856
100. Hohlfels E, McAuley J, Mack D, Milhous W, McLeod R 1994. In vitro effects of artemisinin ether, cycloguanil hydrochloride (alone and in combination with sulfadiazine), quinine sulfate, mefloquine, primaquine phosphate, trifluoperazine hydrochloride and verapamil on Toxoplasma gondii. Antimicrob Agents Chemother 38: 1392-1396.
101. Jamieson SE, de Roubaix LA, Cortina-Borja M, Tan HK, Mui EJ, Cordell HJ, Kirisits MJ, Miller EN, Peacock CS, Hargrave AC, Coyne JJ, Boyer K, Bessieres MH, Buffolano W, Ferret N, Franck J, Kieffer F, Meier P, Nowakowska DE, Paul M, Peyron F, Stray-Pedersen B, Prusa AR, Thulliez P, Wallon M, Petersen E, McLeod R, Gilbert RE, Blackwell JM 2008. Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS ONE 3: e2285.
102. Justus J 1968. Congenital toxoplasmosis with dermatitis calcificans toxoplasmatica and tetany of the mother during delivery. Dtsch Med Wochenschr 93: 349-353.
103. Khodr G, Matossian R 1978. Hydrops fetales and congenital toxoplasmosis. Value of direct immunofluorescence test. Obstet Gynecol 51: 74S-77S.
104. Kieffer F, Wallon M, Garcia P, Thulliez P, Peyron F, Franck J 2008. Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis. Pediatr Infect Dis J 27: 27-32.
105. Kim K 2006. Time to screen for congenital toxoplasmosis? Clin Infect Dis 42: 1395-1397.
106. Kodjikian L, Wallon, Fleury M, Denis P, Binquet C, Peyron F, Garweg JG 2006. Ocular manifestations in congenital toxoplasmosis. Graefes Arch Clin Exp Ophthalmol 244: 14-21.
107. Koppe JG, Kloosterman GJ 1982. Congenital toxoplasmosis: longterm follow-up. Padiatr Padol 17: 171-179.
108. Koppe JG, Loewer-Sieger DH, DeRoever-Bonnet H 1986. Results of 20-year follow-up of congenital toxoplasmosis. Lancet 1: 254-256.
109. Kozar Z, Dluzewski L, Dluzewska A, Jaraszewski Z 1954. Toxoplasmosis as a cause of mental deficiency. Neurol Neurochir Pol 4: 383-396.
110. Kräubig H 1963. Erste praktische Erfahrungen mit der Prophylaze der konnatalen Toxoplasmose. Med Klin 58: 1361-1364.
111. Kräubig H 1966. Preventive method of treatment of congenital toxoplasmosis. In H Kirchhoff, H Kräubig (eds.), Toxoplasmose. Praktische Fragen und Ergebnisse, G Thieme Verlag, Stuttgart, p. 104-122.
112. Kvirikadze VV, Yourkova IA 1961. On the role of congenital toxoplasmosis in the origin of oligophrenia and of its certain other forms of mental ailments. Zh Nevropatol Psikhiatr 61: 1059-1062.
113. Labadie MD, Hazemann JJ 1984. Contribution of health check-ups in children to the detection and epidemiologic study of congenital toxoplasmosis. Ann Pediatr (Paris) 31: 823-828.
114. Lehmann T, Marcet PL, Graham DH, Dahl ER, Dubey JP 2006. Globalization and the population structure of Toxoplasma gondii. Proc Natl Acad Sci USA 103: 11423-11428.
115. Leport C, Vilde JL, Katlama C, Regnier B, Matheron S, Saimot AG 1986. Failure of spiramycin to prevent neurotoxoplasmosis in immunosuppressed patients (letter to the editor). Med Clin North Am 70: 677-692.
116. Levin M, McLeod R, Young Q, Abrahams C, Chambliss C, Walzer PD, Kabins SA 1983. Pneumocystis pneumonia: importance of gallium scan for early diagnosis and description of a new immunoperoxidase technique to demonstrate P. carinii. Am Rev Resp Dis 128: 182-185.
117. Lynfield R, Hsu HW, Guerina NG 1999. Screening methods for congenital Toxoplasma and risk of disease. Lancet 353: 1899-1900.
118. Mack D, Johnson J, Roberts F, Roberts C, Estes R, David C, Grumet C, Estes R, McLeod R 1999. HLA-Class II genes modify outcome of Toxoplasma gondii infection. Int J Parasitol 29: 1351-1358.
119. Mack DG, McLeod R 1984. A new micromethod to study effects of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine and study of clindamycin, metronidazole, and cyclosporine A. Antimicrob Agents Chemother 26: 26-30.
120. Mackie MJ, Fiscus AG, Pallister P 1971. A study to determine causal relationships of toxoplasmosis to mental retardation. Am J Epidemiol 94: 215-221.
121. Margit T, Istvan ER 1983. Congenital toxoplasmosis causing diabetes insipidus. Orv Hetil 124: 827-829.
122. Massa G, Vanderschueren-Lodeweyckx M, Van Vliet G, Craen M, de Zegher F, Eggermont E 1989. Hypothalamo-pituitary dysfunction in congenital toxoplasmosis. Eur J Pediatr 148: 742-744.
123. McAuley J, Roizen N, Patel D, Beckman J, Schey W, Stein L, Wolters C, Johnson D, Meier P, Mack DG, Mets M, Boyer K, Swisher C, Withers S, Holfels E, McLeod R 1994. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: The Chicago Collaborative Treatment Trial. Clin Inf Dis 18:38-72.
124. McCabe R, Remington JS 1988. Toxoplasmosis: the time has come. Editorial. N Engl J Med 318: 313-315.
125. McGee T, Wolters C, Stein L, Kraus N, Johnson D, Boyer K, Mets M, Roizen N, Beckman J, Meier P, Swisher C, Holfels E, Withers S, McLeod R 1992. Absence of sensorineural hearing loss in treated infants and children with congenital toxoplasmosis. Otolarygol Head Neck Surg 106: 75-80.
126. McLeod R, Berry PF, Marshall WH Jr, Hunt SA, Ryning FW, Remington JS 1979. Toxoplasmosis presenting as brain abscesses. Diagnosis by computerized tomography and cytology of aspirated purulent material. Am J Med 67: 711-714.
127. McLeod R, Boyer K, Karrison T, Kasza K, Swisher C, Roizen N, Jalbrzikowski J, Remington J, Heydemann P, Noble AG, Mets M, Holfels E, Withers S, Latkany P, Meier P, Toxoplasmosis Study Group 2006a. Outcomes of treatment of congenital toxoplasmosis, 1981-2004. The National Collaborative Chicago-based Congenital Toxoplasmosis Study (NCCCTS). CID 42: 1383-1394.
128. McLeod R, Khan AR, Noble GA, Latkany P, Jalbrzikowski J, Boyer K, Toxoplasmosis Study Group 2006b. Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis. Pediatr Infect Dis 25:270-272.
129. McLeod R, Mack D, Foss R, Boyer K, Withers S, Levin S, Hubbel J 1992. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Antimicrob Ag Chemother 36: 1040-1048.
130. McLeod R, Remington JS 2006. Toxoplasmosis. In RL Behrman, VC Vaughan, III, WE Nelson (eds.), Nelson's Textbook of Pediatrics 18th ed., WB Saunders, Philadelphia, 1486-1495.
131. Meenken C, Assies J, van Nieuwenhuizen O, Holwerda-van der Maat WG, van Schooneveld MJ, Delleman WJ, Kinds G, Rothova A 1995. Long term ocular and neurological involvement in severe congenital toxoplasmosis. Br J Ophthalmol 79: 581-584.
132. Meneceur P, Bouldouyre MA, Aubert D, Villena I, Menotti J, Sauvage V, Garin JF, Derouin F 2008. In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine and atovaquone. Antimicrob Agents Chemother 52: 1269-1277.
133. Mets MB, Holfels E, Boyer KM, Swisher CN, Roizen N, Stein L, Stein M, Hopkins J, Withers S, Mack D, Luciano R, Patel D, Remington JS, Meier P, McLeod R 1996. Eye manifestations of congenital toxoplasmosis. Am J Opthalmol 122: 309-324.
134. Michels KB, Rothman KJ 2003. Update on unethical use of placebos in randomized trials. Bioethics 17: 188-204.
135. Montoya JG, Remington JS 2008. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis 47: 554-566.
136. Mui EJ, Schiehser GA, Milhous WK, Hsu H, Roberts CW, Kirisits M, Muench S, Rice D, Dubey JP, Fowble JW, Rathod PK, Queener SF, Liu SR, Jacobus DP, McLeod R 2008. Novel triazine JPC- 2067-B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis 2: e190.
137. Mussbichler H 1968. Radiologic study of intracranial calcifications in congenital toxoplasmosis. Acta Radiol Diagn (Stockh) 7: 369-379.
138. O'Connor GR 1974. Manifestations and management of ocular toxoplasmosis. Bull NY Acad Med 50: 192-210.
139. Oygür N, Yilmaz G, Özkaynak C, Guven AG 1998. Central diabetes insipitus in a patient with congenital toxoplasmosis. Am J Perinatol 15: 191-192.
140. Paige BH, Cowen D, Wolf A 1942. Toxoplasmic encephalomyelitis. V. Further observations of infantile toxoplasmosis; intrauterine inception of the disease; visceral manifestations. Am J Dis Child 63: 474-514.
141. Parissi G 1973. Essai d'évaluation du risqué de poussée évolutive secondaire de choriorétinite dans la toxoplasmose congénitale. Paris, Thése Paris-Saint-Antoine. Paris, France.
142. Patel DV, Holfels EM, Vogel NP, Boyer KM, Mets MB, Swisher CN, Roizen NJ, Stein LK, Stein MA, Hopkins J, Withers SE, Mack DG, Luciano RA, Meier P, Remington JS, McLeod RL 1996. Resolution of intracranial calcifications in infants with treated congenital toxoplasmosis. Radiology 199: 433-440.
143. Perkins ES 1973. Ocular toxoplasmosis. Br J Ophthalmol 57: 1-17.
144. Perkins ES, Smith CH, Schofield PB 1956. Treatment of uveitis with pyrimethamine (Daraprim). Br J Ophthalmol 40: 577-586.
145. Petrof E, McLeod R 2002. Toxoplasma gondii and Toxoplasmosis. In L Badour, S Gorbach (eds.), Therapy of infectious diseases, WB Saunders, Philadelphia, p. 653-696.
146. Peyron F, Lobry JR, Musset K, Ferrandiz J, Gomez-Marin JE, Petersen E, Meroni V, Rausher B, Mercier C, Picot S, Cesbron-Delauw MF 2006. Serotyping of Toxoplasma gondii in chronically infected pregnant women: predominance of type II in Europe and types I and III in Colombia (South America). Microbes Infect 8: 2333-2340.
147. Peyron F, Wallon M, Bernardoux C 1996. Long-term follow-up of patients with congenital ocular toxoplasmosis (letter). N Engl J Med 334: 993-994.
148. Phan L, Kasza K, Jalbrzikowski J, Noble AG, Latkany P, Kuo A, Mieler W, Meyers S, Rabiah P, Boyer K, Swisher C, Mets M, Roizen N, Cezar S, Remington J, Meier P, McLeod R, Toxoplasmosis Study Group 2008a. Longitudinal study of new eye lesions in treated congenital toxoplasmosis. Ophthalmology 115: 553-559.
149. Phan L, Kasza K, Jalbrzikowski J, Noble AG, Latkany P, Kuo A, Mieler W, Meyers S, Rabiah P, Boyer K, Swisher C, Mets M, Roizen N, Cezar S, Sautter M, Remington J, Meier P, McLeod R, Toxoplasmosis Study Group 2008b. Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. Am J Ophthalmol 146: 375-384.
150. Piketty C, Derouin F, Rouveix B, Pocidalo JJ 1990. In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice. Antimicrob Agents Chemother 34: 1467-1472.
151. Portela RW, Bethony J, Costa MI, Gazzinelli A, Vitor RW, Hermeto FM, Correa-Oliveira R, Gazzinelli RT 2004. A multihousehold study reveals a positive correlation between age, severity of ocular toxoplasmosis and levels of glycoinositolphospholipid-specific immunoglobulin A. J Infect Dis 190: 175-183.
152. Potasman I, Davidovich M, Tal Y, Tal J, Zelnik N, Jaffe M 1995. Congenital toxoplasmosis: a significant cause of neurological morbidity in Israel? Clin Infect Dis 20: 259-262.
153. Puissan C, Desmonts G, Mozziconacci P 1971. Evolutivité neurologique tardive d'une toxoplasmose congénitale démontrée par l'étude du L.C.R. Ann Pediatr (Paris) 18: 224-227.
154. Puri S, Spencer RP, Gordon ME 1974. Positive brain scan in toxoplasmosis. J Nucl Med 15: 641-642.
155. Remington JS, McLeod R, Thulliez P, Desmonts G 2006. Toxoplasmosis. In J Remington, G Klein, C Wilson, C Baker (eds.), Infectious diseases of the fetus and newborn infant, 6th ed., WB Saunders, Philadelphia, p. 947-1091.
156. Ristow W 1966. On the problem of the etiological importance of toxoplasmosis in hearing disorders, especially in deaf-mutism. Z Laryngol Rhinol Otol 45: 251-264.
157. Roberts F, Kuo A, Roberts CW, Jones L, McLeod R 2008. Ocular toxoplasmosis: clinical features, pathology, pathogenesis, animal models and immune response. In J Ajioka, D Soldati-Favre (eds.), Toxoplasma: molecular and cellular biology, Elsevier, London, p. 59-92.
158. Roberts F, McLeod R 1999. Pathogenesis of toxoplasmic retinochoroiditis. Parasitol Today 15: 51-57.
159. Roberts F, Mets MB, Ferguson DJ, O'Grady R, O'Grady C, Thulliez P, Brézin AP, McLeod R 2001. Histopathological features of ocular toxoplasmosis in the fetus and infant. Arch Ophthalmol 119: 51-58.
160. Roberts T, Frenkel JK 1990. Estimating income losses and other preventable costs caused by congenital toxoplasmosis in people in the United States. J Am Vet Med Assoc 196: 249-56.
161. Roizen N, Kasza K, Karrison T, Mets M, Noble AG, Boyer K, Swisher C, Meier P, Remington J, Jalbrzikowski J, McLeod R, Kipp M, Rabiah P, Chamot D, Estes R, Cezar S, Mack D, Pfiffner L, Stein M, Danis B, Patel D, Hopkins J, Holfels E, Stein L, Withers S, Cameron A, Perkins J, Heydemann P 2006. Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics 118: e379-390.
162. Roizen N, Swisher CN, Stein MA, Hopkins J, Boyer KM, Holfels E, Mets MB, Stein L, Patel D, Meier P, Withers S, Remington J, Mack D, Heydemann P, Patton D, McLeod R 1995. Neurologic and developmental outcome in treated congenital toxoplasmosis. Pediatrics 95: 11-20.
163. Romand S, Chosson M, Franck J, Wallon M, Kieffer F, Kaiser K, Dumon H, Peyron F, Thulliez P, Picot S 2004. Usefulness of quantitative polymerase chain reaction in amniotic fluid as early prognostic marker of fetal infection with Toxoplasma gondii. Am J Obstet Gynecol 190: 797-802.
164. Romand S, Wallon M, Franck J, Thulliez P, Peyron F, Dumon H 2001. Prenatal diagnosis using polymerase chain reaction on amniotic fluid for congenital toxoplasmosis. Obstet Gynecol 97: 296-300.
165. Roper HP 1986. A treatable cause of hydrops fetalis. J Royal Soc Med 79: 109-110.
166. Rothova A 1993. Ocular involvement in toxoplasmosis. Br J Ophthalmol 77: 371-377.
167. Roussel B, Pinon JM, Birembaut P, Rullier J, Pennaforte F 1987. Congenital nephrotic syndrome associated with congenital toxoplasmosis. Arch Fr Pediatr 44: 795-797.
168. Ryning FW, McLeod R, Maddox JC, Hunt S, Remington JS 1979. Probable transmission of Toxoplasma gondii by organ transplantation. Ann Intern Med 90: 47-49.
169. Sabin AB, Feldman HA 1949. Chorioretinopathy associated with other evidence of cerebral damage in childhood; a syndrome of unknown etiology separable from congenital toxoplasmosis. J Pediatr 35: 296-309.
170. Salt A, Freeman K, Prusa A, Ferret N, Buffolano W, Malm G, Schmidt D, Tan HK, Gilbert RE, Petersen E, European Multicentre Study on Congenital Toxoplasmosis 2005. Determinants of response to a parent questionnaire about development and behaviour in 3 year olds: European multicentre study of congenital toxoplasmosis. BMC Pediatr 5: 21.
171. Saxon SA, Knight W, Reynolds DW, Stagno S, Alford CA 1973. Intellectual deficits in children born with subclinical congenital toxoplasmosis: a preliminary report. J Pediatr 82: 792-797.
172. Schoondermark-van de Ven E, Galama J, Vree T, Camps W, Baars I, Eskes T, Meuwissen J, Melchers W 1995. Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine. Antimicrob Agents Chemother 39: 137-144.
173. Schubert W 1957. Fruchttod und Hydrops universalis durch Toxoplasmose. Virchows Arch 330: 518-524.
174. Sheffield HG, Melton ML 1975. Effect of pyrimethamine and sulfadiazine on the fine structure and multiplication of Toxoplasma gondii in cell cultures. J Parasitol 61: 704-712.
175. Siliaeva NF 1965. A case of congenital toxoplasmic meningoencephalitis complicated by an edematous form of symptomatic erythroblastosis. Arkhiv Patologii 27: 67-70.
176. Silveira C, Belfort R Jr, Muccioli C, Holland GN, Victora CG, Horta BL, Yu F, Nussenblatt RB 2002. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol 134: 41-46.
177. Stagno S, Reynolds DW, Amos CS, Dahle AJ, McCollister FP, Mohindra I, Ermocilla R, Alford CA 1977. Auditory and visual defects resulting from symptomatic and subclinical congenital cytomegaloviral and Toxoplasma infections. Pediatrics 56: 669-678.
178. Stanford MR, Tan HK, Gilbert RE 2006. Toxoplasmic retinochoroiditis presenting in childhood: clinical findings in a UK survey. Br J Ophthalmol 90: 1464-1467.
179. Stern H, Booth JC, Elek SD, Fleck DG 1969. Microbial causes of mental retardation. The role of prenatal infections with cytomegalovirus, rubella virus, and Toxoplasma. Lancet 2: 443-448.
180. SYROCOT - Systematic Review on Congenital Toxoplasmosis Study Group, Thiébaut R, Leproust S, Chêne G, Gilbert R 2007. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet 369: 115-122.
181. Swisher CN, Boyer K, McLeod R 1994. The Toxoplasmosis Study Group. Congenital toxoplasmosis. Semin Pediatr Neurol 1: 4-25.
182. Thalhammer O 1969. Congenital toxoplasmosis in Vienna. Summering (sic) findings and opinions. In L Specia (ed.), Colloque sur la toxoplasmose de la femme enceinte et la prevention de la toxoplasmose congenitale. Monographie, Lyon Medical, p. 109-129.
183. Thalhammer O 1973. Prevention of congenital toxoplasmosis. Neuropediatrie 4: 233-237.
184. Thiébaut R, Leroy V, Alioum A, Binquet C, Poizat G, Salmi LR, Gras L, Salamon R, Gilbert R, Chêne G 2006. Biases in observational studies of the effect of prenatal treatment for congenital toxoplasmosis. Eur J Obstet Gynecol Reprod Biol 124: 3-9.
185. Thulliez P 2001. Commentary: Efficacy of prenatal treatment for toxoplasmosis: a possibility that cannot be ruled out. Int J Epidemiol 30: 1315-1316.
186. Titelbaum DS, Hayward JC, Zimmerman RA 1989. Pachygyriclike changes: topographic appearance at MR imaging and CT and correlation with neurologic status. Radiology 173: 663-667.
187. Torre D, Casari S, Speranza F, Donisi A, Gregis G, Poggio A, Ranieri S, Orani A, Angarano G, Chiodo F, Fiori G, Carosi G 1998. Randomized trial and trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Antimicrob Agents Chemother 42: 1346-1349.
188. Tós-Luty S, Chrzastek-Spruch H, Uminski J 1964. Studies on the frequency of a positive toxoplasmosis reaction in mentally deficient, deaf and normally developed children. Wiad Parazytol 10: 374-376.
189. Trenque T, Marx C, Quereux C, Leroux B, Dupouy D, Dorangeon PH, Choisy H, Pinon JM 1998. Human maternofoetal distribution of pyrimethamine-sulphadoxine (letter). Br J Clin Pharmacol 45: 179-180.
190. Vallochi AL, Nakamura MV, Schlesinger D, Martins MC, Silveira C, Belfort R Jr, Rizzo LV 2002. Ocular toxoplasmosis: more than just what meets the eye. Scand J Immunol 55: 324-328.
191. Vanhaesebrouck P, De Wit M, Smets K, De Praeter C, Leroy JG 1988. Congenital toxoplasmosis presenting as massive neonatal ascites. Helv Paediatr Acta 43: 97-101.
192. Verlinde JD, Makstenieks O 1950. Repeated isolation of Toxoplasma from the cerebrospinal fluid and from the blood, and the antibody response in four cases of congenital toxoplasmosis. Ant van Leeuwen 16: 366-372.
193. Virkola K, Lappalainen M, Valanne L, Kosikiniemi M 1997. Radiological signs in newborns exposed to primary Toxoplasma infection in utero. Pediatr Radiol 27: 133-138.
194. Wallon M, Gandihon F, Peyron F, Mojon M 1994. Toxoplasmosis in pregnancy. Letter to the editor. Lancet 344: 541.
195. Wallon M, Kodjikian L, Binquet C, Garweg J, Fleury J, Quantin C, Peyron F 2004. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics 113: 1567-1572.
196. Weiss LM, Kim K 2004. The International Congress on Toxoplasmosis. Int J Parasitol 34: 249-252.
197. Wilson CB, Remington JS, Stagno S, Reynolds DW 1980. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics 66: 767-774.
198. Wolf A, Cowen D 1937. Granulomatous encephalomyelitis due to an encephalitozoon (encephalitozoic encephalomyelitis): a new protozoan disease of man. Bull Neurol Inst NY 6: 306-371.
199. Wolf A, Cowen D 1938. Granulomatous encephalomyelitis due to a protozoan (Toxoplasma or Encephalitozoon): II. Identification of a case from the literature. Bull Neurol Inst NY 7: 266-283.
200. Wolf A, Cowen D 1939. Human toxoplasmosis: occurrence in infants as an encephalomyelitis. Verification by transmission to animals. In BH Kean, KE Mott, AJ Russell (eds.), Tropical medicine and parasitology: classical investigations, Cornell University Press, Ithaca, p. 282-284.
201. Wolf A, Cowen D 1959. Perinatal infections of the central nervous system. J Neuropathol Exp Neurol 18: 191-243.
202. Wolf A, Cowen D, Paige BH 1939a. Toxoplasmic encephalomyelitis III. A new case of granulomatous encephalomyelitis due to a protozoon. Am J Pathol 15: 657-694.
203. Wolf A, Cowen D, Paige BH 1939b. Toxoplasmic encephalomyelitis. Trans Am Neurol Assoc 65: 76-79.
204. Woods CR, Englund J 1993. Congenital toxoplasmosis presenting with eosinophilic meningitis. Pediatr Infect Dis J 12: 347-348.
205. Wright I 1974. Congenital toxoplasmosis and deafness. An investigation. Pract Otorhinolaryngol (Basel) 33: 377-387.
206. Yamakawa R, Yamashita Y, Yano A, Morita J, Kato H 1996. Congenital toxoplasmosis complicated by central diabetes insipidus in an infant with Down syndrome. Brain Dev 18: 75-77.
207. Zitelli BJ, Alexander J, Taylor S, Miller KD, Howrie DL, Kuritsky JN, Perez TH, Van Thiel DH 1987. Fatal hepatic necrosis due to pyrimethamine sulfadoxine (Fansidar). Ann Intern Med 106: 393-395.
208. Zuther E, Johnson JJ, Haselkorn R, McLeod R, Gornicki P 1999. Growth of Toxoplasma gondii is inhibited by aryloxyphenoxypropionate herbicides targeting acetyl-CoA carboxylase. Proc Natl Acad Sci USA 96: 13387-13392.